Cardiovascular
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sun Backs India-First Stroke Drug From Pharmazz
Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial. The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.
Alnylam/Roche’s Zilebesiran Affirms Efficacy, But Commercially Relevant Data Await
The KARDIA-1 monotherapy study was successful, but KARDIA-2 will give a better sense of the market opportunity.
Corteria Rides Wave Of Renewed Interest In Heart Failure
A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.
Johnson & Johnson Gets Its Aprocitentan Money Back
The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market.
Now Europe’s Most Valuable Company, Can Novo Nordisk Live Up To Investor Expectations?
Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?
Bayer Expands Kerendia Program In Competitive Heart Failure Space
The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of
LIB Therapeutics Has An Unorthodox Funding Method And Big Plans
Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers.
LIB Therapeutics Looks Competitive With Big Pharma in Hypercholesterolemia
Phase III results with lerodalcibep are in the same ballpark as heavy-hitting established PCSK9 inhibiting drugs.
Novartis Lauds Long-Term Benefits Of Leqvio At ESC
Putting aside access issues for Leqvio, Novartis has presented data showing that the small interfering RNA directed PCSK9 twice-a-year injection provides consistent low-density lipoprotein cholesterol reduction over six years and more.
BridgeBio ATTR-CM Data Ignite Discussion Around Financing, Partnerships
The company presented detailed data for acoramidis at the ESC meeting over the weekend, though some data points like time to first CV hospitalization have not yet reported out.
Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables
The drug maker announced the start of a Phase III program for its oral PCSK9 inhibitor MK-0616, including a 14,550-patient outcomes trial set to start later in the year.
Novo Nordisk STEPs Into Heart Failure
The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.